Asset Acquisition, Royalty Percentage

No definition available.

Name:	lnth_AssetAcquisitionRoyaltyPercentage
Namespace Prefix:	lnth_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Business Acquisition, Shares Acquired

+ References

No definition available.

+ Details

Name:	lnth_BusinessAcquisitionSharesAcquired
Namespace Prefix:	lnth_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Payments For Asset Acquisitions

+ References

No definition available.

+ Details

Name:	lnth_PaymentsForAssetAcquisitions
Namespace Prefix:	lnth_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of voting equity interests acquired at the acquisition date in the business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479328/805-10-50-2

+ Details

Name:	us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.

+ References

No definition available.

+ Details

Name:	us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lnth_AgreementWithPerspectiveTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=lnth_PerspectiveTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=lnth_PerspectiveTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=lnth_PerspectiveTherapeuticsIncFullyDilutedBasisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=lnth_PerspectiveCommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=lnth_CerveauTechnologiesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=lnth_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=lnth_ResearchRevenueMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=lnth_POINTBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=lnth_PNT2002LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=lnth_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=lnth_PNT2003LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisition of Assets (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			3 Months Ended		12 Months Ended
	Jan. 08, 2024	May 31, 2023	Feb. 28, 2023	Dec. 31, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2022	Mar. 04, 2024
Asset Acquisition [Line Items]
Research and development					$ 48,024	$ 30,532
Acquisition of exclusive license option					28,000	$ 0
Agreement with Perspective Therapeutics, Inc
Asset Acquisition [Line Items]
Disposal group consideration	$ 8,000
Perspective Therapeutics, Inc
Asset Acquisition [Line Items]
Research and development					$ 28,000
Perspective Therapeutics, Inc \| Licenses
Asset Acquisition [Line Items]
Acquisition of exclusive license option	$ 28,000
Perspective Therapeutics, Inc
Asset Acquisition [Line Items]
Subsidiary, ownership percentage, noncontrolling owner								19.90%
Perspective Therapeutics, Inc, Fully Diluted Basis
Asset Acquisition [Line Items]
Subsidiary, ownership percentage, noncontrolling owner								17.35%
Perspective Common Stock
Asset Acquisition [Line Items]
Shares acquired (in shares)	56,342,355							60,431,039
Percentage of acquired interest	11.39%
Share price (in dollars per share)	$ 0.37							$ 0.95
Cerveau Technologies, Inc
Asset Acquisition [Line Items]
Payment for acquisitions		$ 10,000	$ 35,300
Asset acquisition, additional milestone payments			51,000
Cerveau Technologies, Inc \| Sales Milestones
Asset Acquisition [Line Items]
Asset acquisition, additional milestone payments			1,200,000
Cerveau Technologies, Inc \| Research Revenue Milestones
Asset Acquisition [Line Items]
Asset acquisition, additional milestone payments			$ 13,500
POINT Biopharma
Asset Acquisition [Line Items]
Payment for acquisitions				$ 260,000
Asset acquisition, additional milestone payments				1,800,000
Research and development							$ 260,000
PNT2002 License Agreement
Asset Acquisition [Line Items]
Payment for acquisitions				$ 250,000
Royalty percentage				20.00%
PNT2002 License Agreement \| Sales Milestones
Asset Acquisition [Line Items]
Asset acquisition, additional milestone payments				$ 1,300,000
PNT2002 License Agreement \| Regulatory Milestones
Asset Acquisition [Line Items]
Asset acquisition, additional milestone payments				281,000
PNT2003 License Agreement
Asset Acquisition [Line Items]
Payment for acquisitions				$ 10,000
Royalty percentage				15.00%
PNT2003 License Agreement \| Sales Milestones
Asset Acquisition [Line Items]
Asset acquisition, additional milestone payments				$ 275,000
PNT2003 License Agreement \| Regulatory Milestones
Asset Acquisition [Line Items]
Asset acquisition, additional milestone payments				$ 34,500